Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Shorter (3‑month) adjuvant therapy with oxaliplatin‑based regimens was not shown to be noninferior to the standard 6‑month course for all patients with stage III colon cancer, but was noninferior when CAPOX was used in a lower‑risk subgroup
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics
- Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure